Sunrise Technologies goes for liquidation
This article was originally published in Clinica
Menlo Park, California-based Sunrise Technologies International, manufacturer of refractive surgery technology, has opted for Chapter 7 bankruptcy and will liquidate its assets. The decision, taken last week, comes a year after the company defaulted on a $1m loan repayment (see Clinica No 998, p 17). The company, which produces the holmium Yag laser, treatment with which involves shrinking the collagen around the eyeball, has had to make a series of layoffs in the last year in the wake of mixed reviews for its technology.
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.